Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vertex Pharmaceuticals
(NQ:
VRTX
)
471.12
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
...
29
30
31
32
33
34
35
36
37
...
53
54
Next >
3 Unstoppable Growth Stocks to Buy for 2023 and Beyond
February 13, 2023
The future looks really bright for these businesses -- and their stocks.
Via
The Motley Fool
2 Top Stocks to Buy in February and Hold Forever
February 13, 2023
These healthcare giants are profitable and have wide moats.
Via
The Motley Fool
The Best Stocks To Invest $5,000 in Right Now
February 12, 2023
The time is right for each of these great stocks.
Via
The Motley Fool
These Cheap Growth Stocks Could Supercharge Your Portfolio
February 12, 2023
All of these players are cheap today considering their growth potential.
Via
The Motley Fool
3 Surefire Growth Stocks You Can Buy Right Now
February 11, 2023
Maybe there's no such thing as a sure thing. But these stocks could come close.
Via
The Motley Fool
2 Biotech Stocks That Could Help Set You Up for Life
February 11, 2023
The two companies have seen similar share growth over the past year.
Via
The Motley Fool
2 Top Biotech Stocks Defying the Bear Market
February 08, 2023
These stocks soared in the double digits last year.
Via
The Motley Fool
Vertex Offers Upbeat Guidance After Beating Fourth-Quarter Profit Views
February 07, 2023
The company topped guidance expectations for its cystic fibrosis medicines.
Via
Investor's Business Daily
This Growth Stock Crushed the Market Last Year. 5 Words from the CEO Suggest There's More to Come.
February 11, 2023
Vertex climbed 31% last year even as the overall market fell.
Via
The Motley Fool
Stock Market Pulls Back As Treasury Yields Jump; Google Dives On AI Flop: Weekly Review
February 10, 2023
Is this a normal, healthy pullback or the start of something more?
Via
Investor's Business Daily
3 Stocks That Could Soar Whether There's a New Bull Market or Not
February 10, 2023
These stocks could enjoy their own bull markets regardless of what the overall market does.
Via
The Motley Fool
2 Top Stocks to Buy Without Hesitation in 2023
February 10, 2023
These healthcare giants have a long track record of enriching investors.
Via
The Motley Fool
Is Vertex Pharmaceuticals Stock a Buy Right Now?
February 10, 2023
The drugmaker outperformed the broad market by a mile in 2022, but could there be further gains?
Via
The Motley Fool
Better Bull Market Buy: CRISPR Therapeutics or Vertex Pharmaceuticals?
February 09, 2023
Both stocks should be winners if gene-editing therapy exa-cel wins regulatory approvals.
Via
The Motley Fool
What's Going On With Vertex Pharmaceuticals (VRTX) Stock Wednesday?
February 08, 2023
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares are trading lower by 1.44% to $304.10 Wednesday morning. The company on Tuesday reported fourth-quarter financial results. What Happened?
Via
Benzinga
1 Beaten-Down Stock That Has a Lot to Prove in 2023
February 08, 2023
This biotech looks like a high-risk, high-reward play.
Via
The Motley Fool
Vertex Pharmaceuticals (VRTX) Q4 2022 Earnings Call Transcript
February 08, 2023
VRTX earnings call for the period ending December 31, 2022.
Via
The Motley Fool
Why Vertex Pharmaceuticals Stock Is Moving During Tuesday's After-Hours Session
February 07, 2023
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares are trading marginally lower by 0.82% to $306 during Tuesday's after-hours session.
Via
Benzinga
Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
February 07, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
The 7 Best Biotech Stocks to Buy for February 2023
February 07, 2023
Following the wave of red ink last year, astute investors should target the best biotech stocks to buy this month for strong growth potential.
Via
InvestorPlace
Is Biotech Immunocore About To Make A 25% Price Move?
February 07, 2023
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.
Via
MarketBeat
Topics
ETFs
3 Top Stocks to Buy If There Is a Market Pullback
February 07, 2023
All three of these stocks performed well as the market fell in 2022.
Via
The Motley Fool
3 Nasdaq 100 Stocks to Buy Hand Over Fist in February
February 07, 2023
The growth-focused Nasdaq 100 is home to three exceptional deals.
Via
The Motley Fool
Is a Recession on the Way? Here's What the Top 7 Indicators Say.
February 06, 2023
If these indicators were in a Magic 8 Ball, they'd probably say, "Ask again later."
Via
The Motley Fool
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
February 05, 2023
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?
Via
Talk Markets
3 No-Brainer Growth Stocks to Buy in 2023
February 03, 2023
These stocks all fell by double digits last year.
Via
The Motley Fool
Why Editas Medicine's Shares Jumped This Week
February 03, 2023
The gene-editing biotech's shares have had a strong two-week run.
Via
The Motley Fool
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
February 03, 2023
These companies should be able to carry their momentum well beyond this year.
Via
The Motley Fool
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
February 03, 2023
Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony...
Via
Benzinga
Is Editas Medicine Stock a Buy Now?
February 03, 2023
Layoffs and a thin clinical-stage pipeline aren't very encouraging.
Via
The Motley Fool
< Previous
1
2
...
29
30
31
32
33
34
35
36
37
...
53
54
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.